OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Tasadenoturev active in DIPG	1213
From little subclones grow mighty oaks	1170
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	826
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	823
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	749
Ecological management of the microbiota in patients with cancer	676
Current understanding and management of CAR T cell-associated toxicities	648
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	562
Novel ICI–TKI combination improves HCC outcomes	545
Gut microbiota in colorectal cancer development and therapy	502
Hodgkin lymphoma: great progress with room for improvement	485
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	479
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	469
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	464
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	451
Sacituzumab govitecan plus pembrolizumab improves outcomes	446
A new standard of care for advanced-stage urothelial carcinoma	424
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	382
Ponatinib superior to imatinib in Ph+ ALL	341
Mortality is similar with active monitoring	339
From ESMO 2022	332
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	328
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	321
Belzutifan as a new option in pheochromocytomas and paragangliomas	319
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	318

Sacituzumab tirumotecan improves OS in mTNBC	313
Understanding and overcoming multidrug resistance in cancer	311
Emerging trends in the global burden of colorectal cancer	306
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	304
Humanized mouse models for immuno-oncology research	303
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	302
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	291
Craniospinal irradiation improves leptomeningeal metastasis control	289
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	274
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	260
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	247
Vebreltinib effective in MET-amplified NSCLC	244
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	235
Improving outcomes in patients with oesophageal cancer	229
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	227
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	207
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	207
Biomarkers for immunotherapy of hepatocellular carcinoma	201
Spatial landscapes of cancers: insights and opportunities	196
MicroRNAs in oncology: a translational perspective in the era of AI	192
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	188
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	184
New CAPSTONE of SCLC therapy?	181
SHINE a light: frontline ibrutinib for MCL	178
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	164
Women with clinically node negative breast cancer can safely avoid axillary surgery	160
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	156
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	154
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	152
Prospective comparisons support the use of navigational bronchoscopy	138
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	136
DREAMseq of therapy for BRAF-mutant melanoma	129
From ESMO 2023: advances in lung cancer	128
Circulating tumour DNA — looking beyond the blood	126
Mitigating acute chemotherapy-associated adverse events in patients with cancer	124
Targeting chromosomal instability in patients with cancer	124
Long-term outcomes following CAR T cell therapy: what we know so far	124
Multiomics STEP up in correlative analysis of response to CAR T cells	118
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	118
From the ESMO Congress 2023	114
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	112
Sentinel lymph node biopsy improves surgical management of cervical cancer	111
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	108
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	107
Newly approved cancer drugs in China — innovation and clinical benefit	103
Author Correction: Innovative approaches for lung cancer screening and interception	100
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	99
Claudin 18.2 as a novel therapeutic target	99
Lung cancer in patients who have never smoked — an emerging disease	94

Clinical implications of T cell exhaustion for cancer immunotherapy	94
Enhancing immunotherapy with tumour-responsive nanomaterials	93
Targeted biopsy reduces detection of clinically insignificant cancer	90
T-DXd effective as second-line therapy in G/GEJ cancers	88
Less-frequent surveillance is noninferior to annual mammography	88
Second-line tarlatamab improves OS in SCLC	88
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	87
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	84
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	82
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	80
Two decades of advances in clinical oncology — lessons learned and future directions	79
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	79
Translating biological insights into improved management of endometrial cancer	78
Barriers in access to oncology drugs — a global crisis	78
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	78
HSCT prolongs remission of high-risk CTCLs	77
BrECADD raises the bar in classical Hodgkin lymphoma	77
Nirogacestat effective in desmoid tumours	68
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	63
Thermal ablation is safer than resection of colorectal liver lesions	61
Cured but breathless: the growing burden of DIILD in cancer survivors	60
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	59
Promising OS with oncolytic virotherapy	59
GPRC5D-CAR T cells active in MM	58
Non-financial conflicts of interest	55
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	55
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	53
Promise with co-administration of CAR T cells	53
Engineering platelets as cancer therapeutics	52
Multidisciplinary management of meningiomas in the era of precision oncology	52
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	51
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	50
Exploiting bacteria for cancer immunotherapy	46
The current state of the art and future trends in RAS-targeted cancer therapies	46
Efficacy of TILs confirmed	46
Repotrectinib effective in ROS1-fusion-positive NSCLC	44
KN046 shows tolerability and activity in TNBC	43
The emerging roles of γδ T cells in cancer immunotherapy	42
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	41
Problematic crossovers in cancer drug trials	39
Neoadjuvant pembrolizumab improves outcomes	38
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	37
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	37
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	30
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	29
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	29
GPRC5D as a novel immunotherapeutic target in multiple myeloma	28
CAR T cells induce durable remission of neuroblastoma	28
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	28
National value-based pricing negotiation for oncology drugs — lessons from China	28
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	27
The changing landscape of oncology clinical trials in Latin America	26
Personalizing adjuvant therapy for patients with colorectal cancer	26
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	25